BROADEN2 Enrollment Completion Sets Up for Major YE26 Catalyst

Research evidence excerpt

BROADEN2 Enrollment Completion Sets Up for Major YE26 Catalyst

p with, the following company: 4D

Molecular Therapeutics Inc, Aardvark Therapeutics Inc., Abivax, ABSCI CORP, Acadia Pharmaceuticals Inc, Adagene Inc., AgomAb Therapeutics NV, Alector Inc, Alnylam Pharmaceuticals Inc,

Alumis Inc., Amgen Inc., Arcus Biosciences Inc., Arcutis Biotherapeutics, Inc., argenx SE, Arrowhead Pharmaceuticals Inc, Arvinas Inc, Ascendis Pharma A/S, Atea Pharmaceuticals Inc, Avalyn

Pharma Inc, Axsome Therapeutics, Belite Bio Inc, BeOne Medicines, Bicara Therapeutics, BioAge Labs Inc, Biogen Inc, Biohaven Ltd, Biomarin Pharmaceutical Inc, BioNTech SE, BridgeBio Oncology

Therapeutics, BridgeBio Pharma Inc, Cabaletta Bio Inc, Centessa Pharmaceuticals, Inc, CG Oncology, Compass Pathways PLC, Contineum Therapeutics, Crinetics Pharmaceuticals, CRISPR

Therapeutics AG, Cullinan Therapeutics, Cytokinetics Inc, Denali Therapeutics Inc, Disc Medicine Inc, Dyne Therapeutics Inc, Eikon Therapeutics Inc, Erasca, Inc., Evommune Inc, Exelixis Inc., Fractyl

Health Inc, Generate Biomedicines Inc, Genmab A/S, Gilead Sciences Inc., Halozyme Therapeutics, Inc, Immix Biopharma, Immunocore Holdings Ltd, Incyte Corp, Insmed Inc, Intellia Therapeutics

Inc, Ionis Pharmaceuticals Inc, Kalaris Therapeutics, Kymera Therapeutics Inc, Kyverna Therapeutics, Lakefront Biotherapeutics, Legend Biotech Corp, MapLight Therapeutics, Mirum

Pharmaceuticals, Moderna Inc, Monopar Therapeutics, Neurocrine Biosciences Inc, Nurix Therapeutics Inc., Pharvaris N.V., Prime Medicine Inc, ProKidney Corp, PTC Therapeutics, Recursion

Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc., Regenxbio Inc, Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, Sana Biotechnology, Inc, Sarepta Therapeutics Inc, Schrodinger